160 related articles for article (PubMed ID: 19088802)
1. Beneficial effect of 3,4,5,6-tetrahydroxyxanthone on dyslipidemia in apolipoprotein E-deficient mice.
Xiao HB; Sun ZL; Lu XY; Li DZ; Xu JP; Hu YP
Can J Physiol Pharmacol; 2008 Dec; 86(12):815-26. PubMed ID: 19088802
[TBL] [Abstract][Full Text] [Related]
2. Undaria pinnatifida soluble fiber regulates Angptl3-LPL pathway to lessen hyperlipidemia in mice.
Xiao HB; Lu XY; Zhang HB; Sun ZL; Fang J
J Physiol Biochem; 2013 Dec; 69(4):719-25. PubMed ID: 23595961
[TBL] [Abstract][Full Text] [Related]
3. 1,3,5,8-tetrahydroxyxanthone regulates ANGPTL3-LPL pathway to lessen the ketosis in mice.
Xiao HB; Sun ZL; Zhou N
Eur J Pharm Sci; 2012 May; 46(1-2):26-31. PubMed ID: 22342712
[TBL] [Abstract][Full Text] [Related]
4. Paeoniflorin regulates GALNT2-ANGPTL3-LPL pathway to attenuate dyslipidemia in mice.
Xiao HB; Liang L; Luo ZF; Sun ZL
Eur J Pharmacol; 2018 Oct; 836():122-128. PubMed ID: 30096295
[TBL] [Abstract][Full Text] [Related]
5. A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice.
Ando Y; Shimizugawa T; Takeshita S; Ono M; Shimamura M; Koishi R; Furukawa H
J Lipid Res; 2003 Jun; 44(6):1216-23. PubMed ID: 12671033
[TBL] [Abstract][Full Text] [Related]
6. The Citrus Flavonoid Nobiletin Downregulates Angiopoietin-like Protein 3 (ANGPTL3) Expression and Exhibits Lipid-Modulating Effects in Hepatic Cells and Adult Zebrafish Models.
Lin CY; Chen PY; Hsu HJ; Gao WY; Wu MJ; Yen JH
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293338
[TBL] [Abstract][Full Text] [Related]
7. ANGPTL3 is part of the machinery causing dyslipidemia majorily via LPL inhibition in mastitis mice.
Xiao HB; Wang JY; Sun ZL
Exp Mol Pathol; 2017 Dec; 103(3):242-248. PubMed ID: 29104012
[TBL] [Abstract][Full Text] [Related]
8. Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor.
Inaba T; Matsuda M; Shimamura M; Takei N; Terasaka N; Ando Y; Yasumo H; Koishi R; Makishima M; Shimomura I
J Biol Chem; 2003 Jun; 278(24):21344-51. PubMed ID: 12672813
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion.
Wang Y; Gusarova V; Banfi S; Gromada J; Cohen JC; Hobbs HH
J Lipid Res; 2015 Jul; 56(7):1296-307. PubMed ID: 25954050
[TBL] [Abstract][Full Text] [Related]
10. Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL).
Lee EC; Desai U; Gololobov G; Hong S; Feng X; Yu XC; Gay J; Wilganowski N; Gao C; Du LL; Chen J; Hu Y; Zhao S; Kirkpatrick L; Schneider M; Zambrowicz BP; Landes G; Powell DR; Sonnenburg WK
J Biol Chem; 2009 May; 284(20):13735-13745. PubMed ID: 19318355
[TBL] [Abstract][Full Text] [Related]
11. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
[TBL] [Abstract][Full Text] [Related]
12. Physiological roles and regulation of hepatic angiopoietin-like protein 3 in Japanese Black cattle (Bos taurus) during the fattening period.
Shikida R; Kim M; Futohashi M; Nishihara K; Lee H; Suzuki Y; Baek Y; Masaki T; Ikuta K; Iwamoto E; Uemoto Y; Haga S; Terada F; Roh S
J Anim Sci; 2023 Jan; 101():. PubMed ID: 37317898
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
Graham MJ; Lee RG; Brandt TA; Tai LJ; Fu W; Peralta R; Yu R; Hurh E; Paz E; McEvoy BW; Baker BF; Pham NC; Digenio A; Hughes SG; Geary RS; Witztum JL; Crooke RM; Tsimikas S
N Engl J Med; 2017 Jul; 377(3):222-232. PubMed ID: 28538111
[TBL] [Abstract][Full Text] [Related]
14. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys.
Gusarova V; Alexa CA; Wang Y; Rafique A; Kim JH; Buckler D; Mintah IJ; Shihanian LM; Cohen JC; Hobbs HH; Xin Y; Valenzuela DM; Murphy AJ; Yancopoulos GD; Gromada J
J Lipid Res; 2015 Jul; 56(7):1308-17. PubMed ID: 25964512
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
Chen Y; Duan Y; Yang X; Sun L; Liu M; Wang Q; Ma X; Zhang W; Li X; Hu W; Miao RQ; Xiang R; Hajjar DP; Han J
Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299
[TBL] [Abstract][Full Text] [Related]
16. Xanthohumol, a prenylated chalcone, regulates lipid metabolism by modulating the LXRα/RXR-ANGPTL3-LPL axis in hepatic cell lines and high-fat diet-fed zebrafish models.
Gao WY; Chen PY; Hsu HJ; Liou JW; Wu CL; Wu MJ; Yen JH
Biomed Pharmacother; 2024 May; 174():116598. PubMed ID: 38615609
[TBL] [Abstract][Full Text] [Related]
17. The effect of T0901317 on ATP-binding cassette transporter A1 and Niemann-Pick type C1 in apoE-/- mice.
Dai XY; Ou X; Hao XR; Cao DL; Tang YL; Hu YW; Li XX; Tang CK
J Cardiovasc Pharmacol; 2008 May; 51(5):467-75. PubMed ID: 18437096
[TBL] [Abstract][Full Text] [Related]
18. Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia.
Chen PY; Gao WY; Liou JW; Lin CY; Wu MJ; Yen JH
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298929
[TBL] [Abstract][Full Text] [Related]
19. Liver X receptor agonist T0901317 reduces atherosclerotic lesions in apoE-/- mice by up-regulating NPC1 expression.
Ou X; Dai X; Long Z; Tang Y; Cao D; Hao X; Hu Y; Li X; Tang C
Sci China C Life Sci; 2008 May; 51(5):418-29. PubMed ID: 18785587
[TBL] [Abstract][Full Text] [Related]
20. Angiopoietin-like protein 3 inhibits lipoprotein lipase activity through enhancing its cleavage by proprotein convertases.
Liu J; Afroza H; Rader DJ; Jin W
J Biol Chem; 2010 Sep; 285(36):27561-70. PubMed ID: 20581395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
